Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.

Kasper RecourtJasper van der AartGabriel JacobsMarieke de KamWayne DrevetsLuc van NuetenKawita KanhaiPieter SiebengaRob G J A ZuikerPaulien RavenstijnMaarten TimmersJoop van GervenPeter De Boer

Published in: Journal of psychopharmacology (Oxford, England) (2020)

Overall, the observed pharmacological profile of JNJ-54175446 in the dexamphetamine challenge paradigm is compatible with a potential mood-modulating effect.

Keyphrases

placebo controlled
double blind
phase iii
phase ii
study protocol
clinical trial
open label
phase ii study
bipolar disorder
signaling pathway
sleep quality
risk assessment
physical activity